Michael R.  Jaff net worth and biography

Michael Jaff Biography and Net Worth

Director of HeartBeam

Dr. Michael R. Jaff is currently Chief Medical Officer and Vice President of Clinical Affairs, Technology and Innovation of the Peripheral Interventions division at Boston Scientific Corporation. Previously, he was a professor of medicine at Harvard Medical School and he served as President of Newton-Wellesley Hospital. Prior to that, Dr. Jaff was the inaugural Paul and Phyllis Fireman Endowed Chair of Vascular Medicine and Medical Director of the Fireman Vascular Center at the Massachusetts General Hospital. He is a recognized expert in all aspects of vascular medicine and is the founder of VasCore, the Vascular Ultrasound Core Laboratory. Dr. Jaff has published over 300 peer-reviewed publications and 10 textbooks and is the Past-President of the Society for Vascular Medicine. Dr. Jaff received a B.S. from Dickinson College, a D.O. from Kirksville College of Osteopathic Medicine, a Business degree from Harvard Business School and an honorary Doctorate of Arts from Harvard Medical School.

What is Michael R. Jaff's net worth?

The estimated net worth of Michael R. Jaff is at least $11.50 thousand as of April 16th, 2026. Dr. Jaff owns 31,250 shares of HeartBeam stock worth more than $11,497 as of September 30th. This net worth estimate does not reflect any other assets that Dr. Jaff may own. Learn More about Michael R. Jaff's net worth.

How do I contact Michael R. Jaff?

The corporate mailing address for Dr. Jaff and other HeartBeam executives is 1000 CEDAR HOLLOW ROAD, MALVERN PA, 19355. HeartBeam can also be reached via phone at 610-729-7000 and via email at [email protected]. Learn More on Michael R. Jaff's contact information.

Has Michael R. Jaff been buying or selling shares of HeartBeam?

Michael R. Jaff has not been actively trading shares of HeartBeam during the last ninety days. Most recently, on Thursday, April 16th, Michael R. Jaff bought 31,250 shares of HeartBeam stock. The stock was acquired at an average cost of $0.80 per share, with a total value of $25,000.00. Following the completion of the transaction, the director now directly owns 31,250 shares of the company's stock, valued at $25,000. Learn More on Michael R. Jaff's trading history.

Who are HeartBeam's active insiders?

HeartBeam's insider roster includes Michael Jaff (Director), Marga Ortigas-Wedekind (Director), and Branislav Vajdic (President, Director). Learn More on HeartBeam's active insiders.

Are insiders buying or selling shares of HeartBeam?

In the last year, HeartBeam insiders bought shares 7 times. They purchased a total of 1,118,750 shares worth more than $895,000.00. In the last year, insiders at the medical research company sold shares 3 times. They sold a total of 307,146 shares worth more than $1,077,090.03. The most recent insider tranaction occured on April, 16th when CFO Tim Cruickshank bought 31,250 shares worth more than $25,000.00. Insiders at HeartBeam own 18.0% of the company. Learn More about insider trades at HeartBeam.

Information on this page was last updated on 4/16/2026.

Michael R. Jaff Insider Trading History at HeartBeam

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2026Buy31,250$0.80$25,000.0031,250View SEC Filing Icon  
See Full Table

Michael R. Jaff Buying and Selling Activity at HeartBeam

This chart shows Michael R. Jaff's buying and selling at HeartBeam by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

HeartBeam Company Overview

HeartBeam logo
BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.
Read More

Today's Range

Now: $0.37
Low: $0.36
High: $0.38

50 Day Range

MA: $0.47
Low: $0.36
High: $0.59

2 Week Range

Now: $0.37
Low: $0.36
High: $4.00

Volume

4,039 shs

Average Volume

973,169 shs

Market Capitalization

$20.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A